China's HUTCHMED climbs as AstraZeneca applies for US cancer drug approval
29/09/2026 03:22
BUZZ-China's HUTCHMED climbs as AstraZeneca applies for US cancer drug approval ** Shares of HUTCHMED (China) 0013.HK climb 4.1% to HK$23.1, their highest level since September 4
** Stock on track for its biggest one-day pct gain since September 21
** HUTCHMED said on Tuesday that Anglo-Swedish drugmaker AstraZeneca AZN.L had applied to the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination to treat patients with advanced lung cancer
** ORPATHYS is being jointly developed by AstraZeneca and HUTCHMED and is commercialised by AstraZeneca
** YTD, HUTCHMED's Hong Kong stock up 11%, Hang Seng Biotech Index .HSBIO up 14%
(Reporting by Donny Kwok)
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation